Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
暂无分享,去创建一个
R. Larson | M. Liedtke | R. Levine | J. Maciejewski | M. Tallman | W. Stock | H. Carraway | A. Advani | M. Sekeres | M. Kalaycio | A. Nazha | B. Przychodzen | C. Kerr | S. Mukherjee | A. Gerds | R. Sobecks | Ilana R Yurkiewicz | C. Saygin | R. Cassaday | B. Hamilton | Jae H. Park | A. Kishtagari | Natalie M Reizine | R. Levine
[1] A. Logan,et al. Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[2] F. Gao,et al. Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data. , 2018, Leukemia research.
[3] A. Krishnan,et al. Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma , 2018, Leukemia.
[4] T. Slavin,et al. Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients , 2018, Haematologica.
[5] A. Chanan-Khan,et al. Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes , 2017, Cancer medicine.
[6] J. Maciejewski,et al. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Maciejewski,et al. Rational management approach to pure red cell aplasia , 2017, Haematologica.
[8] Patrick W. Burke,et al. NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[9] J. Paulus,et al. Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance , 2017, Blood Cancer Journal.
[10] M. Arcila,et al. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[11] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[12] J. Hernández-Rivas,et al. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy , 2016, Leukemia & lymphoma.
[13] V. Bhatt,et al. Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis. , 2015, Leukemia research.
[14] M. Nørgaard,et al. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Devlin,et al. Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy , 2015, British journal of haematology.
[16] I. Aldoss,et al. Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcome , 2015, Bone Marrow Transplantation.
[17] L. Möllgård,et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population‐based setting: A report from the Swedish Acute Leukemia Registry , 2015, American journal of hematology.
[18] Christopher A. Miller,et al. The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.
[19] Daniel J Weisdorf,et al. Acute Myeloid Leukemia. , 2015, The New England journal of medicine.
[20] H. Brenner,et al. Survival of Adults with Acute Lymphoblastic Leukemia in Germany and the United States , 2014, PloS one.
[21] S. Kamel‐Reid,et al. Therapy‐related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis , 2012, Cancer.
[22] H. Kantarjian,et al. Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related? , 2012, Haematologica.
[23] R. Larson,et al. Therapy-related myeloid leukemia. , 2008, Seminars in oncology.
[24] B. Wood,et al. 9-color and 10-color flow cytometry in the clinical laboratory. , 2006, Archives of pathology & laboratory medicine.
[25] W. Hiddemann,et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML , 2004, Leukemia.
[26] James Allan,et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.